Good morning, everyone, and how are you today? We are doing just fine, thank you, especially now that the middle of the week is here. After all, this means just a few days are left until the weekend arrives. So keep plugging away. After all, what are the alternatives? While you ponder the possibilities, we will keep busy brewing another cup of stimulation — mocha nut fudge is our choice today, for no particular reason — and forage for interesting items. Meanwhile, here are some tidbits to get you going. Have a splendid day and we hope you conquer the world. …

Four lawmakers from the Senate and House introduced a bill to prohibit illegal marketing and distribution of opioids; create criminal liability for top company executives; penalize drug makers who illegally advertise, market or distribute an opioid product; and require drug makers to reimburse the country for the negative economic impact of their products. The move comes after former Insys Therapeutics (INSY) executives were convicted of bribing doctors to prescribe an addictive opioid and Rochester Distributor executives were indicted for failing to monitor opioid shipments.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • No, this is not my blog, but may I take issue with this wording in the Novartis piece? “The drug may cost up to $5 million.”
    Uh, no – it can’t “cost” anything like that, as it implies a link to the actual production of same. The ‘usurious charge by NVS may be up to 5 Million USD’ but that will NOT be their cost.”

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy